Published in Basic Res Cardiol on May 10, 2016
Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol (2016) 0.87
From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on "New frontiers in cardiovascular research". Basic Res Cardiol (2016) 0.79
Dynamic Edematous Response of the Human Heart to Myocardial Infarction: Implications for Assessing Myocardial Area at Risk and Salvage. Circulation (2017) 0.76
Remote ischaemic conditioning in the context of type 2 diabetes and neuropathy: the case for repeat application as a novel therapy for lower extremity ulceration. Cardiovasc Diabetol (2016) 0.75
Ischemia/Reperfusion Injury following Acute Myocardial Infarction: A Critical Issue for Clinicians and Forensic Pathologists. Mediators Inflamm (2017) 0.75
At the crossroads from bench to bedside: luteolin is a promising pharmacological agent against myocardial ischemia reperfusion injury. Ann Transl Med (2016) 0.75
Intermittent pacing therapy favorably modulates infarct remodeling. Basic Res Cardiol (2017) 0.75
Modeling oxygen requirements in ischemic cardiomyocytes. J Biol Chem (2017) 0.75
New and revisited approaches to preserving the reperfused myocardium. Nat Rev Cardiol (2017) 0.75
Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation (1986) 19.82
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med (2008) 9.40
Cyclosporine before PCI in Patients with Acute Myocardial Infarction. N Engl J Med (2015) 5.90
A Multicenter Trial of Remote Ischemic Preconditioning for Heart Surgery. N Engl J Med (2015) 4.22
New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res (2004) 3.63
Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. N Engl J Med (2015) 3.60
The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation (2014) 2.99
Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res (2002) 2.84
ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovasc Res (2014) 2.24
Final infarct size measured by cardiovascular magnetic resonance in patients with ST elevation myocardial infarction predicts long-term clinical outcome: an observational study. Eur Heart J Cardiovasc Imaging (2012) 2.12
Propofol cardioplegia: A single-center, placebo-controlled, randomized controlled trial. J Thorac Cardiovasc Surg (2015) 2.06
Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation (2007) 1.91
Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J (2006) 1.86
Remote ischemic conditioning. J Am Coll Cardiol (2015) 1.66
New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation (2011) 1.66
Inhibition of anoxia-induced injury in heart myocytes by cyclosporin A. J Mol Cell Cardiol (1991) 1.64
Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res (2015) 1.64
The war against heart failure: the Lancet lecture. Lancet (2014) 1.63
Cyclosporine A in Reperfused Myocardial Infarction: The Multicenter, Controlled, Open-Label CYCLE Trial. J Am Coll Cardiol (2016) 1.60
Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial. Eur Heart J (2013) 1.58
Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol - a clinical trial. Acta Anaesthesiol Scand (2011) 1.53
Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol (2015) 1.52
Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J (2015) 1.48
Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev (2014) 1.47
Trends and outcomes of valve surgery: 16-year results of Netherlands Cardiac Surgery National Database. Eur J Cardiothorac Surg (2014) 1.47
Cardiovascular remodelling in coronary artery disease and heart failure. Lancet (2014) 1.47
Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway? J Mol Cell Cardiol (2009) 1.40
Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol (2003) 1.33
The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury. J Mol Cell Cardiol (2014) 1.30
Intralipid, a clinically safe compound, protects the heart against ischemia-reperfusion injury more efficiently than cyclosporine-A. Anesthesiology (2012) 1.27
Cell death, damage-associated molecular patterns, and sterile inflammation in cardiovascular disease. Arterioscler Thromb Vasc Biol (2011) 1.17
The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol (2001) 1.16
Na(+)/H(+) exchange inhibitors for cardioprotective therapy: progress, problems and prospects. J Am Coll Cardiol (2002) 1.10
A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med (1983) 1.06
Role of bradykinin in preconditioning and protection of the ischaemic myocardium. Br J Pharmacol (2002) 1.06
Platelet P2Y₁₂ blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther (2012) 1.04
Release of a humoral circulating cardioprotective factor by remote ischemic preconditioning is dependent on preserved neural pathways in diabetic patients. Basic Res Cardiol (2012) 1.04
Cyclosporine A at reperfusion reduces infarct size in pigs. Cardiovasc Drugs Ther (2010) 1.04
Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol (2014) 1.02
NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. Cardiovasc Res (2011) 1.01
Repeated remote ischemic postconditioning protects against adverse left ventricular remodeling and improves survival in a rat model of myocardial infarction. Circ Res (2011) 1.00
Remote ischemic conditioning and cardioprotection: a systematic review and meta-analysis of randomized clinical trials. Basic Res Cardiol (2015) 0.97
Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts. Thromb Haemost (2010) 0.96
Novel therapeutic strategies for cardioprotection. Pharmacol Ther (2014) 0.94
Cardiac effects of postconditioning depend critically on the duration of index ischemia. Am J Physiol Heart Circ Physiol (2006) 0.93
Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta-analysis. Br J Pharmacol (2012) 0.91
Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. J Am Coll Cardiol (2000) 0.91
ERICCA and RIPHeart: two nails in the coffin for cardioprotection by remote ischemic conditioning? Probably not! Eur Heart J (2015) 0.89
The remote ischemic preconditioning algorithm: effect of number of cycles, cycle duration and effector organ mass on efficacy of protection. Basic Res Cardiol (2016) 0.87
The role and modulation of autophagy in experimental models of myocardial ischemia-reperfusion injury. J Geriatr Cardiol (2014) 0.85
The mitochondrial permeability transition pore in AD 2016: An update. Biochim Biophys Acta (2016) 0.84
AMISTAD trials: possible reasons for lack of success. J Am Coll Cardiol (2006) 0.84
Endothelial NOS activity and myocardial oxygen metabolism define the salvageable ischemic time window for ischemic postconditioning. Am J Physiol Heart Circ Physiol (2011) 0.84
Mitochondrially targeted Endonuclease III has a powerful anti-infarct effect in an in vivo rat model of myocardial ischemia/reperfusion. Basic Res Cardiol (2015) 0.83
Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. Eur Heart J (2006) 0.83
Perspectives on the therapeutic modulation of an alternative cell death, programmed necrosis (review). Int J Mol Med (2014) 0.82
Changing outcomes of coronary revascularization in British Columbia, 1995-2001. Can J Cardiol (2006) 0.82
Effects of P2Y12 receptor antagonists beyond platelet inhibition - comparison of ticagrelor with thienopyridines. Br J Pharmacol (2016) 0.81
Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol. Int J Cardiol (2010) 0.81
Effect of remote ischaemic conditioning on clinical outcomes in patients presenting with an ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J (2015) 0.81
Matrix metalloproteinase inhibition protects CyPD knockout mice independently of RISK/mPTP signalling: a parallel pathway to protection. Basic Res Cardiol (2013) 0.81
A retrospective analysis of myocardial preservation techniques during coronary artery bypass graft surgery: are we protecting the heart? J Cardiothorac Surg (2014) 0.80
Open heart surgery: one-year self-assessment of quality of life and functional outcome. Ann Thorac Surg (2003) 0.80
Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction. Circulation (1983) 0.80
The coronary circulation in cardioprotection: more than just one confounder. Cardiovasc Res (2011) 0.79
CIRCUS: a kiss of death for cardioprotection? Cardiovasc Res (2015) 0.79
Cyclosporine A at reperfusion fails to reduce infarct size in the in vivo rat heart. Basic Res Cardiol (2013) 0.78
The Effect of Remote Ischemic Conditioning and Glyceryl Trinitrate on Perioperative Myocardial Injury in Cardiac Bypass Surgery Patients: Rationale and Design of the ERIC-GTN Study. Clin Cardiol (2015) 0.78
Remote ischemic conditioning: Current clinical perspectives. J Cardiol (2015) 0.77
Nitroglycerin does not interfere with protection by remote ischemic preconditioning in patients with surgical coronary revascularization under isoflurane anesthesia. Cardiovasc Drugs Ther (2013) 0.77
Cardioprotective Properties of the Platelet P2Y12 Receptor Inhibitor, Cangrelor: Protective in Diabetics and Reliant Upon the Presence of Blood. Cardiovasc Drugs Ther (2015) 0.76
Cangrelor-Mediated Cardioprotection Requires Platelets and Sphingosine Phosphorylation. Cardiovasc Drugs Ther (2016) 0.75